- Home
- MIRM vs CNTA Comparison
MIRM vs CNTA Comparison
Compare MIRM & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | CNTA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.1B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIRM | CNTA |
|---|---|---|
| Price | $93.69 | $39.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $115.33 | $43.17 |
| AVG Volume (30 Days) | 702.8K | ★ 4.8M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,138,000.00 | $15,000,000.00 |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $22.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.18 | $10.95 |
| 52 Week High | $109.28 | $40.26 |
Technical Indicators
Market Signals| Indicator | MIRM | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 74.39 |
| Support Level | $85.35 | $39.16 |
| Resistance Level | $98.03 | $40.26 |
| Average True Range (ATR) | 3.39 | 0.28 |
| MACD | 0.06 | -0.20 |
| Stochastic Oscillator | 20.06 | 39.76 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.